Global Biz. Division Invites doctors from the Philippines to join an academic seminar on Stillen®




The Global Business Division of the Dong-A Pharmaceutical invited doctors from the Philippines to join an
academic seminar on Stillen®.




Stillen® is now being exported to the Philippines as it was endorsed by the Philippine Bureau of Foods and
Drugs (FBFAD) in last May. The seminar consisted of two presentations - ‘Pre-Clinical Results of Stillen®’
by Director Ahn, Byung-Ok of Dong-A Pharmaceutical’s New Drug R&D Laboratory and ‘Phase III Clinical Trial
Results of Stillen® and Clinical Trial Results on Prevention of Gastritis with Non-Steroidal Antiinflamatory
Drug’ by Professor Lee, Keon-Young of the Gastroenterology at the Hanyang Univ. Hospital and a Q&A session.
The seminar joined by more than 20 physicians from the Philippines in total went on for about 2 hours and a
half in the heat of exceptional attention to and interest in Stillen® demonstrated by all of the attending
physicians.




President Kim, Won-Bae commented in his opening remark, “I would like to thank all of you for coming all the
way to Korea in spite of your busy schedule,” and introduced, “Stillen® is the 1st new drug developed
independently by Dong-a Pharmaceutical of which efficacy is now recognized not only in Korea but also
around the world.” He then stated, “We are confident that Stillen® will be a blessing for the patients
suffering stomach disorders and Stillen® will expand its penetration from the Philippines into many other
countries including China, Russia and Turkey.”




Following arduous efforts of more than 10 years which began in 1993, Stillen® was launched as the 1st
mucoprotective action enhancer against noxious agents of Korea in December, 2002 and its safety and efficacy
was certified in PMS (Post-Marketing Surveillance) programs of several authorities. Stillen®’s remarkable
revenue is the most salient evidence of its efficacy. Its revenue jumped from KRW 6.9 billion in 2003 to KRW 34.6
billion in 2005, passing KRE 60 billion mark last year. Dong-A Pharmaceutical is expected to continue with the
exceptional winning streak of Stillen® with KRW 80 billion estimated as the revenue target for this year.




Dong-A Pharmaceutical has consummated an export deal with not only the Philippines but also China and,
given the remarkable efficacy and exceptionally few side-effects, its export volume is expected to grow leaps
and bound every year. Stillen® has already rocked the landscape of mucoprotective action enhancer market
in Korea as a leading product and is about to make a significant dent in the global market.